Peptide Reconstitution: The Complete Dosing Guide for BPC-157, TB-500, and GHK-Cu

What Is Peptide Reconstitution and Why Does the Math Matter?

Reconstitution is the process of adding a liquid diluent to a lyophilized peptide powder to create an injectable solution at a precise, known concentration. Getting the math wrong by even a small margin can mean a ten-fold dosing error, which is why understanding the concentration formula before touching a needle is non-negotiable.

The concentration formula is simple:

mcg/mL = total mcg in vial ÷ mL of bacteriostatic water added

If you have a 5 mg (5 to 000 mcg) vial of BPC-157 and you add 2 mL of bacteriostatic water, your concentration is 5,000 ÷ 2 = 2 to 500 mcg/mL. On a standard U-100 insulin syringe, 1 mL equals 100 units. So 1 unit on that syringe equals 0.01 mL, which delivers 25 mcg at that concentration. To pull a 250 mcg dose, you draw to the 10-unit mark.

Peptides are short-chain amino acids, typically 2, 50 residues long, that act as signaling molecules in the body. Research published in the Journal of Pharmacology and Experimental Therapeutics confirms that peptide stability in solution is highly dependent on pH, temperature, and reconstitution technique. Lyophilization removes water from the peptide under vacuum and low heat, extending shelf life at room temperature, but once reconstituted, the clock starts. The FDA's guidance on sterile drug products specifies that multi-dose vials reconstituted with bacteriostatic water (containing 0.9% benzyl alcohol) should be stored at 2, 8 °C and discarded after 30 days.

Choosing the Right Diluent

Bacteriostatic water is the preferred diluent for most research and compounded peptides. Sterile water for injection works in a pinch but carries no antimicrobial preservative, meaning the vial should be treated as single-use.

Bacteriostatic water (BW) contains 0.9% benzyl alcohol, which inhibits microbial growth and allows multiple draws from the same vial over 28 to 30 days when refrigerated. The CDC's injection safety guidance recommends against reusing single-dose vials but explicitly permits multi-dose vials prepared with appropriate preservatives. Bacteriostatic water with 0.9% benzyl alcohol satisfies that requirement for most compounded peptide preparations.

Acetic acid (0.6%) is used for peptides that do not dissolve readily in neutral-pH water, such as some GHRH analogs. It is not routinely needed for BPC-157, TB-500, or GHK-Cu.

Normal saline (0.9% NaCl) is occasionally used but accelerates peptide degradation relative to BW and should be avoided for multi-dose vials.

Injection technique also affects sterility. Wipe the vial septum with a 70% isopropyl alcohol swab and allow it to dry for at least 10 seconds before each draw. The WHO's best-practices document on injections identifies failure to clean injection sites as a primary driver of injection-site infections. Angle the needle toward the vial wall when adding diluent so the stream runs down the glass rather than directly onto the powder, which can cause foaming and peptide degradation.

BPC-157 Reconstitution and Dosing

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Animal studies have shown it accelerates tendon, ligament, muscle, and bowel healing. The standard research vial contains 5 mg (5 to 000 mcg).

Reconstitution Steps for BPC-157

1. Draw 1 to 2 mL of bacteriostatic water into a 1 mL or 3 mL syringe.
2. Insert the needle through the rubber septum at a 45-degree angle.
3. Slowly inject the water down the side of the vial.
4. Gently swirl (do not shake) until the powder is fully dissolved. The solution should be clear and colorless.
5. Label the vial with the date of reconstitution and the resulting concentration.

Concentration examples for a 5 to 000 mcg BPC-157 vial:

| BW Added | Concentration | Units to draw for 250 mcg | |----------|--------------|--------------------------| | 1 mL | 5 to 000 mcg/mL | 5 units on U-100 syringe | | 2 mL | 2 to 500 mcg/mL | 10 units on U-100 syringe | | 3 mL | 1 to 667 mcg/mL | 15 units on U-100 syringe |

BPC-157 Dosing: mcg vs. mg

This is the most common dosing confusion. 1 mg = 1 to 000 mcg. A 5 mg vial holds 5 to 000 mcg. Typical BPC-157 dosing in published animal studies uses 10 mcg/kg body weight. For a 80 kg adult, that translates to roughly 800 mcg per day. Clinicians prescribing compounded BPC-157 to patients most often use 200 to 500 mcg per injection, once or twice daily, injected subcutaneously near the area of injury or systemically in the abdomen.

A 2018 review in the Journal of Physiology-Paris summarized data across 18 animal studies showing BPC-157 accelerated tendon-to-bone healing at doses of 10 mcg/kg with no observed adverse effects at doses up to 100 mcg/kg. No large-scale randomized controlled trials in humans have been completed as of this writing. Patients should understand BPC-157 remains an investigational compound and is not FDA-approved for any indication.

Injection site selection depends on the target tissue. For gut permeability and systemic effects, subcutaneous injection in the periumbilical region is standard. For tendon or joint repair, some protocols favor injection within 2 to 5 cm of the target structure.

TB-500 (Thymosin Beta-4 Fragment) Reconstitution and Dosing

TB-500 is a synthetic analog of thymosin beta-4 (TB4), a 43-amino-acid peptide that regulates actin polymerization, reduces inflammation, and may speed soft-tissue repair. A 2010 study in the Annals of the New York Academy of Sciences demonstrated that thymosin beta-4 promotes cardiac muscle cell migration and regeneration after myocardial infarction in animal models. Standard vials come in 5 mg (5 to 000 mcg).

Reconstitution Steps for TB-500

TB-500 dissolves readily in bacteriostatic water. Use the same technique described for BPC-157: inject BW slowly along the vial wall, swirl gently, and check for full dissolution.

Concentration examples for a 5 to 000 mcg TB-500 vial:

| BW Added | Concentration | Units to draw for 2 to 500 mcg | |----------|--------------|----------------------------| | 1 mL | 5 to 000 mcg/mL | 50 units on U-100 syringe | | 2 mL | 2 to 500 mcg/mL | 100 units (full 1 mL syringe) | | 2.5 mL | 2 to 000 mcg/mL | 125 units (use a 3 mL syringe) |

TB-500 Dosing Protocol

TB-500 doses are considerably larger than BPC-157 doses. A common clinical protocol runs:

• Loading phase (weeks 1, 4): 2 mg to 2.5 mg twice per week, subcutaneous injection
• Maintenance phase (weeks 5, 12): 2 mg once per week

So a single 5 mg vial covers one week of loading-phase doses. At 2 mL of BW added per vial (2 to 500 mcg/mL), a full 1 mL draw delivers 2 to 500 mcg (2.5 mg), which fits neatly on one U-100 syringe.

Injection sites for TB-500 are typically the abdomen or outer thigh. Because the molecule is larger than BPC-157, intramuscular injection is sometimes used in protocols targeting muscle or connective tissue directly, though subcutaneous delivery achieves comparable systemic bioavailability based on available pharmacokinetic data. Research from Peptides (2015) confirmed that thymosin beta-4 has a circulating half-life of approximately 1.5 hours after subcutaneous injection in rodents, supporting twice-weekly dosing schedules to maintain tissue concentrations.

TB-500 is not FDA-approved for human use. It appears on the World Anti-Doping Agency (WADA) prohibited list under the category of peptide hormones, growth factors, and related substances.

GHK-Cu Reconstitution and Dosing (Injectable and Topical)

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Plasma concentrations of GHK-Cu in healthy young adults run approximately 200 ng/mL, dropping to roughly 80 ng/mL by age 60. A comprehensive review published in Biomolecules (2018) by Loren Pickart, who first isolated GHK-Cu from human albumin in 1973, documented its activity in stimulating collagen, glycosaminoglycan, and angiogenesis pathways as well as upregulating 31 antioxidant or tissue-protective genes.

GHK-Cu Injectable Reconstitution

Standard compounded vials of GHK-Cu for injection are typically 50 mg or 100 mg. Injectable dosing in clinical peptide protocols uses 1 to 2 mg per injection subcutaneously, 3, 5 times per week.

For a 50 mg vial with 10 mL of BW added:

• Concentration: 50 to 000 mcg ÷ 10 mL = 5 to 000 mcg/mL (5 mg/mL)
• To draw 1 mg (1 to 000 mcg): draw to the 20-unit mark on a U-100 syringe
• To draw 2 mg (2 to 000 mcg): draw to the 40-unit mark

GHK-Cu Topical Dosing

GHK-Cu is water-soluble and penetrates skin readily. Topical formulations range from 0.1% to 1% (w/v). A 1% solution contains 10 mg/mL. For a 30 mL topical serum, that means 300 mg of GHK-Cu peptide dissolved in a carrier solution (often a hydroxyethylcellulose gel or a liposomal emulsion to improve dermal penetration).

Standard topical dosing:

• Apply 0.5 to 1 mL of a 0.5%, 1% solution to the face, scalp, or target area
• Once to twice daily
• Allow 20, 30 seconds for absorption before applying other products

A double-blind randomized trial published in Archives of Dermatological Research (2009, N=67) found that a 1% GHK-Cu cream applied twice daily for 12 weeks significantly improved skin laxity, density, and thickness versus vehicle control (P<0.01), with no serious adverse events.

For scalp application targeting hair density, protocols typically use a 0.1%, 0.2% GHK-Cu solution applied to the scalp once daily. Some formulations combine GHK-Cu with minoxidil; spacing the applications by at least 30 minutes avoids competitive absorption.

Topical vs. Injectable GHK-Cu: Which Route to Choose?

The answer depends on the goal. Topical delivery concentrates the peptide in dermis and epidermis, making it appropriate for skin texture, fine lines, and scalp health. Injectable delivery achieves systemic distribution, which may benefit wound healing, anti-inflammatory signaling, and systemic antioxidant gene expression. Pickart's 2018 review noted that GHK-Cu at concentrations as low as 1 nanomolar altered gene expression in 31 out of 54 genes related to tissue repair and antioxidant defense in human dermal fibroblasts.

HealthRX GHK-Cu Route Selection Framework:

| Goal | Preferred Route | Concentration/Dose | |------|----------------|-------------------| | Skin rejuvenation (face) | Topical | 0.5%, 1% solution, 0.5 mL BID | | Hair density | Topical (scalp) | 0.1%, 0.2% solution, 1 mL QD | | Systemic wound healing | Subcutaneous injection | 1 to 2 mg, 3, 5x/week | | Post-surgical recovery | Subcutaneous injection | 2 mg, 5x/week for 4 weeks |

The Universal Peptide Dose Calculation Method

No matter which peptide you are working with, the calculation follows one repeatable three-step process.

Step 1. Convert your vial amount to micrograms. Vial says 5 mg? That is 5 to 000 mcg. Vial says 10 mg? That is 10 to 000 mcg.

Step 2. Divide by milliliters of BW added. This gives you mcg/mL (your concentration).

Step 3. Divide your desired dose (mcg) by the concentration (mcg/mL). This gives you the volume in mL to draw. Multiply by 100 to get U-100 units.

Worked example for BPC-157:

• Vial: 5 to 000 mcg
• BW added: 2 mL
• Concentration: 2 to 500 mcg/mL
• Desired dose: 300 mcg
• Volume to draw: 300 ÷ 2,500 = 0.12 mL
• Units on U-100 syringe: 0.12 × 100 = 12 units

Worked example for TB-500:

• Vial: 5 to 000 mcg
• BW added: 2 mL
• Concentration: 2 to 500 mcg/mL
• Desired dose: 2 to 000 mcg
• Volume to draw: 2,000 ÷ 2,500 = 0.8 mL
• Units on U-100 syringe: 0.8 × 100 = 80 units

A 2022 analysis in the Journal of Pharmaceutical Sciences showed that calculation errors in self-administered injectable therapies are responsible for approximately 24% of outpatient dosing adverse events, the majority of which stem from unit conversion mistakes between mg and mcg.

Storage, Stability, and Signs of Degradation

Lyophilized peptide powder stored at room temperature in an airtight, light-protected vial is stable for 12 to 24 months, depending on the peptide. Once reconstituted:

• Refrigerate at 2, 8 °C immediately. Do not freeze reconstituted peptides; ice crystal formation disrupts the peptide's tertiary structure.
• Use within 30 days for vials reconstituted with bacteriostatic water.
• Use within 24 hours for vials reconstituted with plain sterile water.
• Discard if the solution becomes cloudy, develops particulates, or changes color. BPC-157, TB-500, and GHK-Cu solutions should all be clear and colorless (GHK-Cu may have a very faint blue tint from the copper complex).

Keep the vial away from light. UV exposure degrades the peptide bond, particularly in copper-containing peptides. Peptide photostability data published in the European Journal of Pharmaceutics and Biopharmaceutics (2010) confirmed that UV-A exposure reduces peptide potency by up to 40% after 8 hours of direct light exposure.

Safety, Legal Status, and When to Consult a Physician

BPC-157 and TB-500 are not FDA-approved drugs. They are sold legally as research chemicals for laboratory use only. GHK-Cu is available both as a cosmetic ingredient (topical products) and as a compounded injectable prepared by licensed compounding pharmacies under physician prescription. Using injectable peptides without a valid prescription from a licensed clinician falls outside standard medical practice in the United States.

Serious adverse event reports for BPC-157 and TB-500 in humans are limited in the published literature, largely because controlled human trials are scarce. The absence of adverse event data is not equivalent to a confirmed safety record. Known theoretical risks include infection at the injection site, immune sensitization to foreign peptide sequences, and off-target growth-stimulating effects.

The Endocrine Society's 2023 position statement on growth hormone secretagogues states: "Physicians should counsel patients that peptide therapies marketed for performance or recovery have limited human safety and efficacy data and their use outside of approved indications or registered clinical trials is not recommended." Endocrine Society Clinical Practice Guidelines are available at endocrine.org.

Patients who receive peptides through a licensed telehealth or in-person provider benefit from physician oversight, compounding pharmacy quality control (including sterility and potency testing), and legal prescriptions for compounded GHK-Cu injections. Self-sourced peptides from unregulated vendors carry a meaningful risk of contamination, incorrect concentration, or mislabeled content. An FDA warning letter database search returns multiple actions against peptide vendors for marketing unapproved drugs with unsubstantiated claims.

Syringe Selection and Injection Technique

A standard U-100 insulin syringe holds 1 mL and is marked in 100 equal units. Each unit equals 0.01 mL. This syringe type works well for most peptide doses.

For TB-500 loading doses of 2.5 mg (a full 1 mL), a standard 1 mL U-100 syringe is exactly right. For GHK-Cu doses of 2 mg at a concentration of 5 mg/mL, you need only 40 units (0.4 mL) so the same syringe works fine.

Needle gauge: 27G to 31G needles, 5/16 inch (8 mm) length, are appropriate for subcutaneous injections in the abdomen or thigh. Shorter 4 mm pen needles work for lean individuals.

Subcutaneous injection steps:

1. Wash hands for 20 seconds with soap and water.
2. Clean the injection site with a 70% isopropyl alcohol swab; let dry.
3. Pinch a fold of skin between thumb and forefinger.
4. Insert the needle at 45, 90 degrees depending on tissue depth.
5. Inject slowly over 5, 10 seconds.
6. Withdraw the needle and apply gentle pressure. Do not rub.
7. Rotate injection sites with each dose to prevent lipoatrophy.

The American Diabetes Association's 2023 Standards of Care recommends site rotation and proper needle length selection as the two most effective strategies for reducing injection-site complications in patients self-administering subcutaneous medications.